Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability

​In November 2024, the U.S. Food and Drug Administration (FDA) issued a guidance document titled “Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development.” This guidance aims to assist sponsors in incorporating circulating tumor DNA (ctDNA) as a biomarker in early-stage solid tumor clinical trials conducted under investigational new drug applications (INDs) and to support the marketing approval of drugs and biological products targeting these malignancies. U.S. Food and Drug Administration

Understanding ctDNA

Circulating tumor DNA refers to fragments of DNA shed from tumor cells into the bloodstream. Measuring ctDNA offers a minimally invasive method to obtain information about a patient’s cancer, providing insights into tumor dynamics and treatment responses. U.S. Food and Drug Administration

Potential Regulatory and Clinical Applications

The FDA’s guidance outlines several potential uses for ctDNA in early-stage cancer settings:​U.S. Food and Drug Administration+1FDA Access Data+1

1. Patient Selection Based on Molecular Alterations: ctDNA can identify specific genetic mutations or alterations, aiding in selecting patients who may benefit from targeted therapies.​
2. Molecular Residual Disease (MRD) Assessment for Patient Enrichment: Detecting ctDNA post-treatment can help identify patients with residual disease, enabling closer monitoring or additional therapeutic interventions.​U.S. Food and Drug Administration
3. Measuring Response for Drug Development: Quantifying ctDNA levels can serve as an indicator of treatment efficacy, assisting in the evaluation of new therapies.​
4. Early Endpoint in Clinical Trials: Changes in ctDNA levels might act as early endpoints, potentially expediting clinical trial assessments and drug approvals.​U.S. Food and Drug Administration

Assay Considerations

The guidance emphasizes the importance of standardizing ctDNA assays to ensure consistent and reliable results across different laboratories and technologies. Key considerations include:​U.S. Food and Drug Administration

• Types of MRD Assays: Selecting appropriate assays tailored to specific clinical contexts.​U.S. Food and Drug Administration
• Sampling Considerations: Establishing standardized protocols for blood sample collection, processing, and storage to maintain ctDNA integrity.​
• Analytical Validation: Ensuring ctDNA assays undergo rigorous validation to meet regulatory standards, especially when used to support marketing applications.​U.S. Food and Drug Administration

Investigational Device Considerations

For manufacturers developing specific MRD assays for solid tumors intended for clinical use, the guidance recommends consulting the Office of In Vitro Diagnostics in the Center for Devices and Radiological Health (CDRH). This collaboration aims to align assay development with regulatory requirements, facilitating smoother approval processes.​U.S. Food and Drug Administration

Conclusion

The FDA’s guidance on ctDNA underscores its potential to revolutionize cancer drug development and patient management in early-stage solid tumors. By providing a framework for integrating ctDNA into clinical trials and emphasizing assay standardization, the FDA aims to harness ctDNA’s full potential, ultimately improving patient outcomes.

Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability – by Shudarsana Company